Phase 2 Eczema Trial, Recruiting NCT06947993 Sponsor: Novartis Pharmaceuticals Condition: Eczema
Back to Eczema

Phase 2 Eczema Trial, Recruiting

NCT06947993
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to give their written agreement to take part in the study
  • People who have been diagnosed with atopic dermatitis (a type of chronic skin condition causing inflammation and itching) for at least 1 year
  • People whose atopic dermatitis is moderate to severe in intensity

Who may not be able to join:

  • People who have a significant medical condition or active infectious disease (specific conditions are listed in a related document — confirm with trial site)
  • People whose blood tests, urine tests, or heart trace (ECG) results show significant abnormalities
  • People who have another active inflammatory skin condition at the same time
  • People who have a long-term medical condition that is not well controlled and could put them at greater risk during the study, such as uncontrolled diabetes or high blood pressure
  • People who have an unstable medical condition that would likely need treatment with steroid medications taken by mouth or injection, such as uncontrolled asthma
  • Additional criteria may apply depending on which specific treatment is being studied within the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 1-888-669-6682

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
16 May 2025
Est. completion
27 November 2028

Where this trial is recruiting

🇦🇷 Argentina 🇨🇦 Canada 🇨🇳 China 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇯🇵 Japan 🇳🇱 Netherlands 🇵🇱 Poland 🇸🇰 Slovakia 🇰🇷 South Korea 🇪🇸 Spain 🇹🇼 Taiwan 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov